title: Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
abstract: OBJECTIVE
  Details on the therapeutic effects of long-term antimuscarinic therapy have not been reported. Thus, the aim of this study is to evaluate the detailed long-term therapeutic effect of antimuscarinic therapy.
  
  
  METHODS
  All consecutive patients who visited the urologic outpatient clinics of a medical center for treatment of overactive bladder syndrome and received antimuscarinic therapy of 12 months or more were retrospectively reviewed. All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit.
  
  
  RESULTS
  A total of 140 patients had received 12 months or more of antimuscarinic therapy. Sustained therapeutic effects were observed by persistent decreases of IPSS-storage score, IPSS-total score and OABSS score. Moreover, the maximum flow rate did not change over time. A temporary increase in postvoid residual volume and decrease in voiding efficiency were found, but these parameters improved over long-term visits. Side-effects were observed in 81 patients (57.9%) and included dry mouth (n = 58, 41.4%), constipation (n = 48, 34.3%) and blurred vision (n = 4, 2.9%); all side-effects were tolerable. Patients aged 75 years or more (n = 94) had a higher comorbidity rate (n = 46, 48.9%) before treatment but generally exhibited similar therapeutic effects as overall patients; elderly patients could also tolerate side-effects.
  
  
  CONCLUSIONS
  Sustained therapeutic effects were observed in patients who received 12 months or more of antimuscarinic therapy, even in elderly patients. In addition, side-effects in patients receiving long-term therapy were also common but tolerable.
authors: Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, Taiwan.
authors: Sheng-Mou
authors: SM
authors: Hsiao
authors: Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
authors: Ho-Hsiung
authors: HH
authors: Lin
authors: Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan.
authors: Hann-Chorng
authors: HC
authors: Kuo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003248:Constipation / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000069464:Solifenacin Succinate / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D000068737:Tolterodine Tartrate / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics; D014786:Vision Disorders / Q000139:chemically induced; D014987:Xerostomia / Q000139:chemically induced; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D000068737:Tolterodine Tartrate; C005419:oxybutynin; D000069464:Solifenacin Succinate
keywords: muscarinic antagonists; overactive; treatment outcome; urinary bladder